The proposed changes are significant as they modify the way payments are calculated for clinical diagnostic laboratory services, particularly impacting laboratories that provide widely available tests. By introducing a statistical sampling approach, the bill seeks to improve payment accuracy based on a representative sample rather than overwhelming the system with data from every laboratory. This approach aims to balance cost-efficiency with the need for accurate reimbursement rates, potentially benefiting both providers and patients by ensuring adequate payment for services rendered.
Summary
House Bill 1835, titled the 'Saving Access to Laboratory Services Act,' aims to amend Title XVIII of the Social Security Act to enhance the accuracy of market-based Medicare payments for clinical diagnostic laboratory services. The bill introduces provisions for using statistical sampling methodologies to determine payments for widely available laboratory tests instead of requiring individual reporting from all applicable laboratories. This is intended to streamline data collection processes and reduce the administrative burdens on both laboratories and government agencies involved in these payments.
Contention
However, the bill is not without points of contention. Critics may argue that the reliance on statistical sampling might not adequately reflect the diverse scenarios across different laboratories. Some stakeholders could express concerns about the potential for reduced payments if the sampling does not capture the full picture of laboratory service utilization throughout the country. Moreover, the adjustments to reporting periods and payment reduction limits could cause disparities in funding, affecting smaller or rural laboratories uniquely, which may not have the same scale as larger entities.
Requires hospital laboratories and bio-analytical or clinical laboratories to offer test for hepatitis C to certain individuals; authorizes certain laboratories to perform rapid tests for hepatitis C.
Finn Sawyer Access to Cancer Testing Act This bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer. Additionally, the Department of Health and Human Services must establish an education and awareness program for physicians and the public about genomic testing and the role of genetic counselors.